Correlates of uptake of COVID-19 vaccines and motivation to vaccinate among Malawian adults.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
01 08 2023
Historique:
medline: 10 7 2023
pubmed: 3 7 2023
entrez: 2 7 2023
Statut: ppublish

Résumé

COVID-19 vaccine coverage in most countries in Africa remains low. Determinants of uptake need to be better understood to improve vaccination campaigns. Few studies from Africa have identified correlates of COVID-19 vaccination in the general population. We surveyed adults at 32 healthcare facilities across Malawi, purposively sampled to ensure balanced representation of adults with and without HIV. The survey, informed by the World Health Organization's Behavioural and Social Drivers of Vaccination Framework, asked about people's thoughts and feelings about the vaccine, social processes, motivation to vaccinate, and access issues. We classified respondents' COVID-19 vaccination status and willingness to vaccinate, and used multivariable logistic regression to assess correlates of these. Among 837 surveyed individuals (median age was 39 years (IQR 30-49) and 56% were female), 33% were up-to-date on COVID-19 vaccination, 61% were unvaccinated, and 6% were overdue for a second dose. Those up-to-date were more likely to know someone who had died from COVID-19, feel the vaccine is important and safe, and perceive pro-vaccination social norms. Despite prevalent concerns about vaccine side effects, 54% of unvaccinated respondents were willing to vaccinate. Access issues were reported by 28% of unvaccinated but willing respondents. Up-to-date COVID-19 vaccination status was associated with positive attitudes about the vaccine and with perceiving pro-vaccination social norms. Over half of unvaccinated respondents were willing to get vaccinated. Disseminating vaccine safety messages from trusted sources and ensuring local vaccine availability may ultimately increase vaccine uptake.

Identifiants

pubmed: 37394430
doi: 10.1080/21645515.2023.2228168
pmc: PMC10332229
doi:

Substances chimiques

COVID-19 Vaccines 0
Vaccines 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

2228168

Références

Vaccines (Basel). 2022 May 17;10(5):
pubmed: 35632548
Vaccines (Basel). 2022 May 11;10(5):
pubmed: 35632516
BMJ Glob Health. 2021 Sep;6(9):
pubmed: 34593513
Public Health Pract (Oxf). 2022 Nov 23;4:100343
pubmed: 36438628
Nat Hum Behav. 2021 Jul;5(7):947-953
pubmed: 33972767
Hum Vaccin Immunother. 2022 Dec 31;18(1):2034457
pubmed: 35240908
PLoS One. 2022 Mar 3;17(3):e0264633
pubmed: 35239711
BMJ Open. 2022 May 30;12(5):e052432
pubmed: 35636790
PLoS One. 2018 Dec 21;13(12):e0209586
pubmed: 30576388
Lancet. 2023 Jan 7;401(10370):8-10
pubmed: 36354041
Vaccine. 2022 Aug 26;40(36):5313-5321
pubmed: 35953323
Vaccines (Basel). 2021 Jun 18;9(6):
pubmed: 34207018
Vaccine. 2021 Mar 12;39(11):1556-1564
pubmed: 33618947
Expert Rev Vaccines. 2023 Jan-Dec;22(1):180-185
pubmed: 36688599
Int Health. 2023 Jan 3;15(1):77-84
pubmed: 35294960
PLoS One. 2022 May 18;17(5):e0268711
pubmed: 35584110
N Engl J Med. 2022 Mar 24;386(12):1176-1179
pubmed: 35196425
PLoS One. 2022 Apr 21;17(4):e0266724
pubmed: 35446850
BMJ. 2022 Mar 24;376:e070650
pubmed: 35331982
Nat Med. 2021 Aug;27(8):1385-1394
pubmed: 34272499
Vaccines (Basel). 2022 Feb 25;10(3):
pubmed: 35334991
Glob Health Res Policy. 2022 Jul 19;7(1):21
pubmed: 35850783
Nat Med. 2021 Feb;27(2):225-228
pubmed: 33082575
Vaccines (Basel). 2021 Jul 27;9(8):
pubmed: 34451953
Hum Vaccin Immunother. 2022 Dec 31;18(1):1-6
pubmed: 34227914
J Am Pharm Assoc (2003). 2022 Nov-Dec;62(6):1823-1829
pubmed: 35970727
Lancet. 2021 Mar 13;397(10278):1023-1034
pubmed: 33587887
Epidemiol Infect. 2022 Jul 12;150:e143
pubmed: 35818789
BMJ Open. 2021 Dec 15;11(12):e055159
pubmed: 34911723
Lancet. 2022 Apr 16;399(10334):1452-1453
pubmed: 35218695
N Engl J Med. 2021 Apr 8;384(14):1281-1283
pubmed: 33830709
Int Health. 2023 Feb 17;:
pubmed: 36799143
Vaccines (Basel). 2021 Aug 23;9(8):
pubmed: 34452061

Auteurs

Hannah S Whitehead (HS)

Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

John Songo (J)

Implementation Science Department, Partners in Hope, Lilongwe, Malawi.

Khumbo Phiri (K)

Implementation Science Department, Partners in Hope, Lilongwe, Malawi.

Pericles Kalande (P)

Implementation Science Department, Partners in Hope, Lilongwe, Malawi.

Eric Lungu (E)

Implementation Science Department, Partners in Hope, Lilongwe, Malawi.

Sam Phiri (S)

Implementation Science Department, Partners in Hope, Lilongwe, Malawi.
Department of Public Health and Family Medicine, Kamuzu University of Health Sciences, Lilongwe, Malawi.

Joep J van Oosterhout (JJ)

Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Implementation Science Department, Partners in Hope, Lilongwe, Malawi.

Risa M Hoffman (RM)

Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.

Corrina Moucheraud (C)

Department of Health Policy and Management, Fielding School of Public Health, UCLA, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH